Skip to content

Control study early ultrafiltration or diuretics for the treatment of heart failure

A randomized, parallel controlled and multicenter study to assess the efficacy and safety of early ultrafiltration for patient with heart failure

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-15006111
Enrollment
Unknown
Registered
2015-03-12
Start date
2015-03-26
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Interventions

Treatment group:Ultrafiltration
Sham group:Diuretics

Sponsors

Peking University First Hospital, Fu Wai Hospital CAMS&PUMC
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. More than 18 years old, male or non women, 2. Regular diuretics before admission, 3. Main on Congestive heart failure of hospitalized patients (within 24 h) , 4. the performance of the overload capacity, the performance of 2 or more items which were as follows: (1) have a lower limb or lumbosacral region refers to the pitting edema; (2) paroxysmal nocturnal dyspnea and orthopnea (>=30 degree recumbent position); (3) jugular vein engorgement >8 cm; (4) X-ray sternum with pulmonary edema, pulmonary congestion or pleural effusion. 5. signed informed consent, volunteered for the experiment.

Exclusion criteria

Exclusion criteria: 1. the acute coronary syndrome; 2. the renal insufficiency, creatinine acuity 265.8 mu mol/L (3 mg/dL), renal replacement therapy or expected; 3. systolic blood pressure, 90 MMHG or less (signed informed consent); 4. the red blood cells deposited (HCT) 45% or higher; 5. heparin anticoagulation contraindicated or heparin allergy; 6. of severe valvular stenosis; 7. the pericardial tamponade, massive pericardial effusion, pericarditis, restrictive cardiomyopathy; 8. serious with onset, expected to survive six months or less; 9. uncontrolled systemic infection; 10. potassium <3.5 tendency/L; 11. participated in any other drugs or medical devices clinical trials within 1 month; 12. during pregnancy or lactation women; 13. any mental or cognitive impairment, may limit their understanding of informed consent, execution and research the compliance; 14. the researchers believe that education is not suitable for other information to participate in this test.

Design outcomes

Primary

MeasureTime frame
Dyspnea score;

Secondary

MeasureTime frame
Body fluid removal;Total weight loss;NYHA heart function;NT-BNP;

Countries

China

Contacts

Public ContactYong Huo, Jian Zhang
huoyong@263.net.cn+86 10-88398700

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026